Ge Long Hui·2026-02-26 11:12Core Viewpoint - BeiGene (6160.HK) reported a significant increase in global revenue for Q4 2025 and the entire year, indicating strong growth in its financial performance [1] Financial Performance - Global total revenue reached $1.5 billion in Q4 2025, representing a 33% year-over-year increase [1] - Total global revenue for the year amounted to $5.3 billion, reflecting a 40% year-over-year growth [1] - Q4 global sales for the product Baiyueze reached $1.1 billion, up 38% year-over-year [1] - Annual global sales for Baiyueze were $3.9 billion, showing a 49% year-over-year increase [1] Earnings Per Share - GAAP diluted earnings per American Depositary Share (ADS) were $0.58 for Q4 and $2.53 for the full year [1] - Non-GAAP diluted earnings per ADS were $1.95 for Q4 and $8.09 for the full year [1] Future Guidance - The company provided revenue guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion [1]